BioSpace News Archive

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced that it has obtained Good Laboratory Practice certification from Swiss health authorities for preclinical studies.

Net sales for the three months ended November 30, 2021 were $4.6 million as compared to net sales of $1.4 million for the same three months in fiscal 2021, an increase of $3.2 million, or 239%.

Nemaura Medical, Inc. announces the launch for employers and insurers of Miboko, a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application.

Brooklyn ImmunoTherapeutics, Inc. today announces that 18 new patents were issued and 17 new patent applications were filed in 2021.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced the first patient has been dosed with setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, in the Phase 2 DAYBREAK clinical trial to treat the severe obesity and hyperphagia potentially caused by a genetic variant that impairs function of the MC4R pathway.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021 are presented below.

n-Lorem, a nonprofit foundation, today announced the publication of a review article titled “Meeting the Needs of Patients with Ultra-rare Diseases” in Trends in Molecular Medicine (Crooke, S.T., Trends in Molecular Medicine, Advanced Online Publication, January 2022).

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for , Thursday, January 13, 2022 and will provide an update at a future date.

Peptides exhibit a wide array of functions such as governing cell to cell functions, cell transfer, hormonal functions, and others. Due to their broad range of applications, these have emerged as particular interest to scientists.

The Company’s latest testing accomplishments support its long-standing goal of successfully eradicating all of the top ten target antigens from a static sampling of CSF, thereby permitting control of these target antigens to the prescribed homeostasis level under physician care.